Business Context and Reporting Period
This Form 8-K was filed by Galena Biopharma, Inc. on July 7, 2016 (reporting date July 8, 2016). The filing details a registered direct offering, the discontinuation of a Phase 3 clinical trial, and the settlement of significant litigation. Note: The request metadata lists "SELLAS Life Sciences Group, Inc.," but the filing text explicitly identifies the registrant as Galena Biopharma, Inc.
Key Financial Metrics
- Cash Position: Approximately $19.6 million in cash and cash equivalents as of June 30, 2016.
- Restricted Cash: $24 million reserved for a debtor with a 30-day redemption option following the June 29, 2016 announcement of trial discontinuation.
- Revenue: $0 for the quarter ended June 30, 2016.
- Operating Expenses: Approximately $13 million for the quarter ended June 30, 2016.
- Debt Repayment: Paid off a $3.1 million loan with Oxford Finance LLC.
- Offering Proceeds: Agreed to raise approximately $12.6 million via the sale of 28,000,000 shares at $0.45 per share and warrants to purchase 14,000,000 shares at $0.65 per share.
Material Changes and Events
- Clinical Trial Discontinuation: The Phase 3 PRESENT trial was stopped for futility on June 29, 2016, based on an Independent Data Monitoring Committee (IDMC) recommendation. An investigation into the cause is underway, estimated to cost $250,000–$500,000 over three months. Closing costs for the trial are estimated between $4 million and $7 million.
- Litigation Settlements:
- Securities Class Action: Final approval granted for a $20 million settlement. The Company paid $2.3 million in cash (July 1, 2016) and issued 480,053 shares (July 6, 2016); insurance carriers covered $16.7 million.
- Derivative Litigation: Final approval granted for a settlement involving $15 million in cash (paid by insurance carriers) and the cancellation of 1,200,000 director stock options.
- Opt-Out Claims: Resolved for $150,000 cash plus shares, and $1.5 million in shares.
- Warrant Adjustments: Exercise prices for outstanding warrants from 2010, 2011, and 2012 were adjusted downward (e.g., March 2011 warrants adjusted from $0.65 to $0.45).
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management believes existing cash plus net proceeds from the offering will fund operations for at least six months. However, the Company explicitly states it will need to replenish cash prior to the end of 2016. There is substantial doubt about the Company's ability to continue as a going concern if additional funding is not secured.
- Use of Proceeds: Funds from the $12.6 million offering will be used for clinical trials, working capital, and general corporate purposes.
- Authorized Shares: The Company currently lacks sufficient authorized shares to fulfill warrant obligations. If stockholders do not approve an increase within six months, warrant holders may require a repurchase at Black-Scholes value (capped at $3.5 million aggregate).
- Investment Restrictions: The Company agreed not to utilize existing funding agreements with Lincoln Park Capital Fund, MLV & Co., and Maxim Group LLC for 75 days post-closing.
Investor Verification Checklist
- Verify the status of the $24 million restricted cash and whether the debtor has exercised the redemption option.
- Confirm the timeline and outcome of the investigation into the PRESENT trial discontinuation.
- Monitor the stockholder vote required to increase authorized shares to cover warrant obligations.
- Assess the Company's ability to secure additional financing before the end of 2016 to avoid operational scaling or termination.
- Review the impact of the $13 million quarterly operating expense and litigation costs on the remaining cash runway.